Literature DB >> 9735588

Cocaine use early in treatment predicts outcome in a behavioral treatment program.

K L Preston1, K Silverman, S T Higgins, R K Brooner, I Montoya, C R Schuster, E J Cone.   

Abstract

In this evaluation of baseline drug use as a predictor of treatment outcome, cocaine use during a 5-week baseline was compared in methadone maintenance patients who had < 5 (n = 10) versus > or = 5 (n = 9) weeks of abstinence during an experimental cocaine abstinence reinforcement treatment. Cocaine use was evaluated at the 1st and last visit and the 1st and last week of baseline and as a mean across the 5-week baseline treatment; response was calculated as a mean across 12 weeks of experimental treatment. Those who had successful outcomes (abstainers) used significantly less cocaine in the 5-week baseline than those with less successful outcomes (nonabstainers). Differences in cocaine use were not evident in the 1st baseline visit or week, but the abstainers used significantly less cocaine in the last visit and week of baseline compared with the nonabstainers. Cocaine use during baseline provided critical predictors of response to the experimental treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735588     DOI: 10.1037//0022-006x.66.4.691

Source DB:  PubMed          Journal:  J Consult Clin Psychol        ISSN: 0022-006X


  39 in total

1.  A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period.

Authors:  Adam Bisaga; Efrat Aharonovich; Wendy Y Cheng; Frances R Levin; John J Mariani; Wilfrid N Raby; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

2.  Exploring the limits and utility of operant conditioning in the treatment of drug addiction.

Authors:  Kenneth Silverman
Journal:  Behav Anal       Date:  2004

3.  Prevalence of mood and substance use disorders among patients seeking primary care office-based buprenorphine/naloxone treatment.

Authors:  Jonathan D Savant; Declan T Barry; Christopher J Cutter; Michelle T Joy; An Dinh; Richard S Schottenfeld; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2012-07-06       Impact factor: 4.492

4.  Cost-effectiveness of prize-based incentives for stimulant abusers in outpatient psychosocial treatment programs.

Authors:  Todd A Olmstead; Jody L Sindelar; Nancy M Petry
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

5.  Randomized trial of prize-based reinforcement density for simultaneous abstinence from cocaine and heroin.

Authors:  Udi E Ghitza; David H Epstein; John Schmittner; Massoud Vahabzadeh; Jia-Ling Lin; Kenzie L Preston
Journal:  J Consult Clin Psychol       Date:  2007-10

6.  Effect of reinforcement probability and prize size on cocaine and heroin abstinence in prize-based contingency management.

Authors:  Udi E Ghitza; David H Epstein; John Schmittner; Massoud Vahabzadeh; Jia-Ling Lin; Kenzie L Preston
Journal:  J Appl Behav Anal       Date:  2008

7.  Interim treatment: Bridging delays to opioid treatment access.

Authors:  Stacey C Sigmon
Journal:  Prev Med       Date:  2015-04-30       Impact factor: 4.018

8.  Training reinforcement rates, resistance to extinction, and the role of context in reinstatement.

Authors:  Ludmila Miranda-Dukoski; Joshua Bensemann; Christopher A Podlesnik
Journal:  Learn Behav       Date:  2016-03       Impact factor: 1.986

9.  A randomized trial of contingency management reinforcing attendance at treatment: Do duration and timing of reinforcement matter?

Authors:  Nancy M Petry; Sheila M Alessi; Carla J Rash; Danielle Barry; Kathleen M Carroll
Journal:  J Consult Clin Psychol       Date:  2018-10

10.  An adaptive approach for identifying cocaine dependent patients who benefit from extended continuing care.

Authors:  James R McKay; Deborah H A Van Horn; Kevin G Lynch; Megan Ivey; Mark S Cary; Michelle L Drapkin; Donna M Coviello; Jennifer G Plebani
Journal:  J Consult Clin Psychol       Date:  2013-09-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.